Dolasetron is a serotonin 5-HT3 receptor antagonist primarily indicated for the prevention and treatment of nausea and vomiting associated with cancer chemotherapy. To support pharmaceutical analysis,… Read more















Dolasetron is a serotonin 5-HT3 receptor antagonist primarily indicated for the prevention and treatment of nausea and vomiting associated with cancer chemotherapy. To support pharmaceutical analysis, this category provides a comprehensive selection of dolasetron reference standards, including the active pharmaceutical ingredient and its mesylate salt. Laboratories rely on these high-quality compounds, such as pharmacopeial and non-pharmacopeial impurities, to facilitate accurate impurity profiling and method validation. The inclusion of key metabolites like hydrodolasetron and a range of stable isotope labelled compounds, such as dolasetron-d4 and hydrodolasetron-d4, ensures precise quantification in complex biological matrices during pharmacokinetic studies and routine quality control. Accessing these well-characterized materials is essential for maintaining compliance with regulatory standards and ensuring the consistency of analytical testing protocols throughout the development and manufacturing lifecycle of this antiemetic medication.